Virpax Looking to Use MET to Develop Intranasal COVID Vaccine
MWN-AI** Summary
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) is actively pursuing the development of an intranasal mRNA COVID-19 vaccine using its proprietary Molecular Envelope Technology (MET). This innovative approach aims to provide an alternative to traditional lipid-based delivery systems by utilizing a non-lipid polymer that could potentially enhance safety and minimize side effects. The company’s MET has already been successfully employed in its existing drug candidates, Envelta (NES100) and NobrXiol (VRP324), which focus on pain management and the delivery of cannabidiol for epilepsy, respectively.
The intranasal delivery method is particularly appealing, especially for individuals with needle aversion, drawing comparisons to the FluMist vaccine. By innovating the delivery mechanism, Virpax hopes to facilitate easier vaccination processes. NES100, for instance, features a nanotechnology platform designed to enhance the delivery of enkephalins—naturally occurring peptides—into the brain, potentially improving therapeutic outcomes.
Beyond its COVID-19 vaccine initiative, Virpax is also in the regulatory process for several other candidates. These include Probudur™, a long-acting liposomal formulation for post-operative pain management, and Epoladerm™, a topical compound aimed at osteoarthritis pain relief. Notably, the National Institutes of Health (NIH) and the Department of Defense (DOD) have engaged in cooperative research agreements with Virpax, further validating its promising portfolio.
As the company seeks additional partnerships for its product candidates, including those targeting viral infections like SARS-CoV-2, it remains focused on advancing its research while navigating the regulatory landscape. However, investors should approach with caution, considering the inherent risks detailed in the forward-looking statements, especially regarding the required capital for ongoing studies and trials. For more information on its developments and initiatives, visit https://www.virpaxpharma.com.
MWN-AI** Analysis
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) presents a compelling investment opportunity as it advances its innovative approach to vaccine delivery utilizing Molecular Envelope Technology (MET) for an intranasal COVID-19 vaccine. This strategy parallels established methods, such as FluMist, and could offer significant advantages, especially for individuals averse to injections.
The growing emphasis on non-lipid delivery systems stands out as a key differentiator. By leveraging a polymer-based approach instead of lipid encasements for mRNA, Virpax could potentially reduce side effects and enhance safety, appealing to a broader population. Moreover, the expertise derived from their existing products, such as Envelta and NobrXiol, showcases their capability in nanotechnology and drug delivery. These products' promising pre-Investigational New Drug application guidance from the FDA further underscores Virpax's regulatory credibility.
The company is also deeply engaged in a diverse pipeline, focusing on pain management and CNS disorders, which could offer additional revenue streams beyond COVID-19 vaccination. Their comprehensive R&D agreements with reputable organizations like NIH and DOD enhance credibility and may facilitate access to substantial funding, expediting research and development timelines for their candidates.
However, prospective investors should remain aware of the inherent risks, including the required capital for clinical studies and possible regulatory hurdles. With the evolving landscape of vaccines and public health initiatives, the success of a timely and effective COVID-19 vaccine could notably increase Virpax's market valuation.
In conclusion, Virpax Pharmaceuticals is strategically positioned within the biotech sector with its MET innovations. While risks exist, the potential upside from diversifying their portfolio and successfully launching an intranasal vaccine presents a compelling case for investment consideration. Investors should keep a close watch on upcoming clinical trial results and FDA interactions for clearer indicators of future performance.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Virpax Pharmaceuticals, Inc. (Nasdaq: VRPX) (“Virpax” or the “Company”) , a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system (CNS) disorders and anti-viral barrier indications, is looking to use Molecular Envelope Technology (MET) or a similar technology to deliver a mRNA COVID vaccine. Virpax currently uses its MET for Envelta (NES100) and NobrXiol (VRP324).
The Company will look to explore delivery of vaccines via intranasal delivery similar to the FluMist which is used for patients with a fear of needles. The current vaccines in the market use lipid delivery technology to deliver mRNA to induce an immune response via injection. Virpax hopes to use a non-lipid polymer, which may be safer and have less side effects.
NES100 is an enkephalin drug product based on a type of nanotechnology delivery approach. Enkephalin is a naturally occurring (endogenous) peptide that is not easily administered in its original form. We believe that the nanotechnology may enable and enhance the delivery of this metabolically labile peptide drug into the brain. In addition, Virpax uses MET with NobrXiol. NobrXiol is being developed for delivery of cannabidiol in the management of epilepsy in children and adults. NobrXiol utilizes the MET as its delivery system to cross the blood brain barrier, propelling the cannabidiol nanoparticles through the nose to the brain via the olfactory nerve. The drug has received pre-Investigational New Drug application guidance from the U.S. Food and Drug Administration.
About Virpax Pharmaceuticals Inc.
Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage acute and chronic pain, including pain associated with cancer. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking partners for two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit https://www.virpaxpharma.com , and follow us on Twitter, LinkedIn and YouTube.
Forward-Looking Statements
This press release contains certain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, as amended, including those described below. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.
These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events and involve known and unknown risks, uncertainties, and other factors, including the additional capital which will be necessary to complete studies and clinical trials that the Company plans to initiate and other factors listed under “Risk Factors” in the Company’s Annual Report on Form 10-K and Quarterly Reports on Form 10-Q that the Company has filed with the U.S. Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250307334228/en/
Investor Contact:
info@virpaxpharma.com
FAQ**
What specific milestones does Virpax Pharmaceuticals Inc. (VRPX) aim to achieve with its mRNA COVID vaccine delivery using Molecular Envelope Technology (MET) in the next months?
How does Virpax Pharmaceuticals Inc. (VRPX) plan to differentiate its intranasal delivery system from existing lipid-based vaccine technologies currently on the market?
What are the expected timelines for FDA approvals for Virpax Pharmaceuticals Inc. (VRPX)’s candidates like Probudur™ and Envelta™, and how will they impact the company’s financial outlook?
Can you elaborate on the competitive advantages that Virpax Pharmaceuticals Inc. (VRPX) has with its CRADAs with NIH and DOD in advancing its drug development programs?
**MWN-AI FAQ is based on asking OpenAI questions about Virpax Pharmaceuticals Inc. (NASDAQ: VRPX).
NASDAQ: VRPX
VRPX Trading
70.13% G/L:
$0.35 Last:
148,800 Volume:
$0.20 Open:
